Advertisement


Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

ESMO Virtual Congress 2020

Advertisement

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses results from the phase III ASCENT trial, which showed the antibody-drug conjugate sacituzumab govitecan-hziy improved progression-free and overall survival more than standard single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract LBA17).



Related Videos

Skin Cancer
Immunotherapy

Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection

Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III melanoma, as well as a decrease in the incidence of distant and locoregional recurrence (Abstract LBA46).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may have a place in treating patients with metastatic renal cell carcinoma (Abstract 696O_PR).

Kidney Cancer
Immunotherapy

Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy

Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a standard dose of atezolizumab, administered to patients with metastatic advanced clear cell renal cell carcinoma. Dr. Pal reports on response rates and progression-free survival, as well as biologic correlates that may have influenced response (Abstract 702O).

Breast Cancer

Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease

Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses results of the nextMONARCH study, which indicated that combining abemaciclib with tamoxifen improved overall survival. Dr. Hamilton also details adverse events in different arms of the study (Abstract 273O).

Breast Cancer
Immunotherapy

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials

Lisa A. Carey, MD, of the University of North Carolina, discusses phase III results from two IMpassion trials, 130 and 131, which explored, respectively, atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer and first-line paclitaxel with or without atezolizumab for unresectable disease (Abstracts LBA15 and LBA16).

Advertisement

Advertisement




Advertisement